Berkeley Limketkai, MD, PhD
An endoscopic evaluation of every patient with inflammatory bowel disease within a few months of initiating a biologic agent may make sense, according to a study that found an association between this approach and a reduced risk for disease complications.
Although early proactive endoscopy is not routine, several guidelines, including those issued by the International Organization for the Study of IBD, have identified endoscopic remission as the treatment target in